Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Benfotiamine and Omega-3 are closely matched across evidence, studies, and safety.
Verdict
Likely helps
7 of 7 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
18 of 27 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Benfotiamine and Omega-3 have evidence — compare verdict strength side-by-side.
150-600mg daily
With meals
Benfotiamine capsules
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
4-12 weeks
8-12 weeks
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
Vitamin B and its derivatives for diabetic kidney disease
The Cochrane database of systematic reviews (2015) · Meta analysis · n=1354
There is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying progression of DKD.
Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
BMJ open (2022) · Meta analysis · n=364
There was a significant increase in high-density lipoprotein (HDL) (MD, 0.10; 95% CI: 0.10 to 0.20) at 3-month follow-up.
Therapeutic potential of benfotiamine and its molecular targets
European review for medical and pharmacological sciences (2018) · Systematic review
The reduction in AGEs subsequently decreases metabolic stress which benefits vascular complications seen in diabetes.
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
Limited RCT data with mixed results. Meta-analysis found insufficient evidence to determine clear benefit. Conservative estimates based on subset of positive trials showing modest improvements in neuropathic symptoms.
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
AI-estimated from published studies. Interpret as directional guidance.
Both Benfotiamine and Omega-3 are closely matched — the best choice depends on your specific health goals.
For reduce inflammation, Omega-3 has a higher relevance score (90 vs 75).
No known interactions between Benfotiamine and Omega-3 have been documented in our database. However, always consult a healthcare provider before combining supplements.